Ambrx Biopharma Inc.

NasdaqGS:AMAM Stock Report

Market Cap: US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Ambrx Biopharma Management

Management criteria checks 1/4

Ambrx Biopharma's CEO is Dan O'Connor, appointed in Nov 2022, has a tenure of 1.33 years. total yearly compensation is $1.03M, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 1.1 years and 1.5 years respectively.

Key information

Dan O'Connor

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage6.7%
CEO tenure1.3yrs
CEO ownership0.08%
Management average tenure1.1yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Johnson & Johnson's Acquisition Of Ambrx Biopharma: Hold Through It

Jan 11

CEO Compensation Analysis

How has Dan O'Connor's remuneration changed compared to Ambrx Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$67m

Jun 30 2023n/an/a

-US$60m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$1mUS$69k

-US$78m

Compensation vs Market: Dan's total compensation ($USD1.03M) is below average for companies of similar size in the US market ($USD4.96M).

Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.

CEO

Dan O'Connor (58 yo)

1.3yrs

Tenure

US$1,034,168

Compensation

Mr. Daniel J. O'Connor, J.D., also known as Dan, served as an Independent Director of ZyVersa Therapeutics, Inc. since December 13, 2022 until May 2023. He serves as President, CEO and Director of Ambrx Bi...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel O'Connor
CEO, President & Director1.3yrsUS$1.03m0.076%
$ 1.3m
Sonja Nelson
Chief Financial Officer2.8yrsUS$1.73m0.036%
$ 641.7k
Andrew Aromando
Chief Operating Officerless than a yearno data0%
$ 0
Ying Buechler
Chief Technology Officer2.2yrsno datano data
Shawn Zhang
Chief Scientific Officer & GM of China1.4yrsno datano data
Jared Kelly
Senior VPless than a yearno datano data
Robert Azzara
Vice President of Human Capital1yrno datano data
Sandra Aung
Chief Clinical Officer1.1yrsno datano data
Renu Vaish
Chief Regulatory Officerless than a yearno datano data

1.1yrs

Average Tenure

55yo

Average Age

Experienced Management: AMAM's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Daniel O'Connor
CEO, President & Director1.3yrsUS$1.03m0.076%
$ 1.3m
Paul Maier
Independent Director2.1yrsUS$268.55k0%
$ 0
Peter Schultz
Member of Scientific Advisory Boardno datano datano data
Margaret Dalesandro
Directorless than a yearno datano data
Stephen Glover
Chairman of the Boardless than a yearno data0%
$ 0
Stuart Lutzker
Member of Scientific Advisory Boardno datano datano data
Melissa Starovasnik
Member of Scientific Advisory Boardno datano datano data
Jakob Dupont
Member of Scientific Advisory Boardno datano datano data
Kate Hermans
Independent Director1.7yrsUS$555.41k0%
$ 0
Luisa Salter-Cid
Member of Scientific Advisory Boardno datano datano data
Janet Loesberg
Independent Director1.8yrsUS$156.12k0%
$ 0

1.5yrs

Average Tenure

59yo

Average Age

Experienced Board: AMAM's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/06 10:00
End of Day Share Price 2024/03/06 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ambrx Biopharma Inc. is covered by 6 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Yuan ZhiB. Riley Securities, Inc.
Corinne JohnsonGoldman Sachs